Date: 2013-10-18
Type of information: R&D agreement
Compound: aeroallergens
Company: DBV Technologies (France) Stallergènes (France)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: R&D
Action mechanism:
Disease: respiratory allergies
Details: * On May 16, 2013, Stallergenes and DBV Technologies have entered into a strategic research partnership. This partnership combines Stallergenes’ world class know-how in respiratory allergies with DBV’s Viaskin®, a unique platform allowing for epicutaneous desensitization. DBV will conduct all preclinical work, up to proof-of-concept studies using Viaskin® and Stallergenes’ aeroallergens. Stallergenes will finance all of DBV’s research on these aeroallergens and will have development and commercialization rights. In the coming months, the parties will enter into license agreements for each aeroallergen, defining the opt-in terms for development and commercialization. The agreement with Stallergenes will allow DBV to expand its Viaskin® proprietary platform beyond food allergies.
Financial terms:
Latest news: * On October 18, 2013, Stallergenes and DBV Technologies have entered into a research and development agreement for the treatment of birch allergy. This collaboration is the first agreement following their recently announced collaboration focused on developing innovative treatments for respiratory allergies. Under the terms of the agreement, Stallergenes will fully fund DBV\'s preclinical development. The preclinical program will last between 18 and 24 months and DBV will deliver to Stallergenes a clinical product candidate that combines Stallergenes\' birch pollern allergen with DBV\'s Viaskin® epicutaneous delivery technology. Stallergenes will have full development and worldwide commercialisaion rights on the product candidate.
DBV is eligible to receive preclinical, clinical, regulatory and commercial milestone payment totalling up to €145 million, as well as royalties on net sales. In conjuction with this agreement, Stallergenes acquires a 2 % equity position in DBV from existing shareholders.
